Status
Conditions
Treatments
About
The purpose of this study is to compare the risk of major bleeding event among nonvalvular atrial fibrillation patients treated with warfarin, apixaban, dabigatran and rivaroxaban.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
321,182 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal